{"brief_title": "Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study", "brief_summary": "To examine the effectiveness of subcutaneous gamma interferon in reducing severity of Mycobacterium avium- intracellulare (MAI) bacillemia episodes in AIDS patients in an open-label dose-randomized multi-center pilot clinical investigation. To evaluate the safety of gamma interferon given by subcutaneous injection (SC) in the AIDS patient in the presence and absence of AZT therapy.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Trifluridine", "criteria": "Inclusion Criteria Patients must have: - Diagnosis of AIDS and persistent Mycobacterium avium- intracellulare (MAI) bacillemia. - Life expectancy of at least 3 months. - Baseline chest X-ray and EKG (electrocardiogram). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Known hypersensitivity to interferons or other exogenous lymphokine. - History of cardiac abnormality or disease. - History of hypertension. Patients with the following are excluded: - Known hypersensitivity to interferons or other exogenous lymphokine. - History of cardiac abnormality or disease. - History of hypertension. Prior Medication: Excluded within 4 weeks of study entry: - Corticosteroids. - Anti-inflammatory medication (except aspirin). - Changes in the dose of anti-mycobacterial drugs. - Immune agents. Prior Treatment: Excluded within 4 weeks of study entry: - Radiotherapy. Risk Behavior: Excluded: - Intravenous drug abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002037.xml"}